Compare DexCom, Inc. (DXCM) vs Rivian Automotive, Inc. (RIVN) Price & Performance

DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.

DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.

Rivian Automotive (RIVN) trades at $14.33, down slightly by 0.07% on the day, amid a bearish technical outlook but with improving operational trends. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates and reaffirming full-year guidance, though the stock dipped as investors hoped for a forecast upgrade. Financially, revenue growth continues but losses persist, with a net income margin of -54.95% in 2025, while cash burn has moderated from prior years.

The outlook remains challenged by high cash burn and competitive pressures, but cost controls and R2 SUV ramp-up offer a path to profitability. Analyst consensus is cautiously optimistic with a $16.89 price target, though risks include execution delays and EV market volatility. The stock presents a high-risk, high-reward opportunity for investors betting on Rivian's scaling and autonomy initiatives.